Additionally, if novel efforts to create other boron delivery agents are successful (such as those targeted against hormone receptors and nanoparticle and liposome-based boron delivery systems), BNCT may become a possible treatment option even in breast cancer patients with intrinsically low LAT-1 expression. Here, NR4A1 is linked to breast carcinoma.